Optimizing nebulization practice  by Burnett, H.
316 Letters to the Editor 
QUANTITY OF AEROSOL 
The importance of the effect of residual volume on 
quantity of aerosol can be illustrated in the following 
example: 
Nebulizer A 
Fill volume 2 ml, Residual volume 1 ml 
Total output =50% 
Nebulizer A 
Fill volume 4 ml, Residual volume 1 ml 
Total output =75% 
It can be seen that only half of the initial volume is 
nebulized with a 2 ml fill volume and there is a 
significant (50%) increase in total output when we 
move from 2 to 4 ml. 
If we now consider the same two cases with 
Nebulizer B, having a residual volume of 0.5 ml, it 
can be seen that the increase in the total output is less 
significant when we move from 2 to 4 ml. More 
importantly, however, is the fact that Nebulizer B 
with a 2 ml fill volume gives the same total output as 
Nebulizer A with a 4 ml fill volume. 
Nebulizer B 
Fill volume 2 ml, Residual volume 1.5 ml 
Total output =75% 
Nebulizer B 
Fill volume 4 ml, Residual volume 0.5 ml 
Total output =87.5% 
In practice, if the residual volume of a nebulizer is 
inherently high, then it is common to add saline to 
the initial fill volume in an effort to increase total 
output. 
QUALITY OF AEROSOL 
The quality of the aerosol produced by a nebulizer 
is extremely important as this determines how much 
of the aerosol can penetrate the lungs and thus 
deposit drug to the targeted site. In practice, if the 
percentage of output in the respirable range is inher- 
ently low for a particular nebulizer, the only option 
left to increase the quantity of drug depositing in the 
lung is to increase the fill volume. 
TIME TAKEN TO COMPLETE TREATMENT 
Diluting the initial fill volume with saline substan- 
tially increases the treatment time (2). This increase in 
fill volume may have a detrimental effect on the 
prescribed treatment as longer treatment times result 
in poor compliance due to the patient becoming 
irritated, bored or uncomfortable. 
It is often the case that the higher quantity and 
increased quality of aerosol mean longer treatment 
times. However, by designing nebulizers that work 
efficiently and have low residual volumes, it is poss- 
ible to reduce nebulization time at no cost to quantity 
or quality of aerosol produced. One such nebulizer is 
the Sidestream@. In a recent research paper compar- 
ing 17 commercial jet nebulizers, the total output ‘TO 
of Sidestream was significantly greater than all the 
others’ (3), the percentage of output in the respirable 
range (l-5 ,um) ‘PORR of Sidestream was signifi- 
cantly greater than all others’, and the treatment time 
for a 2.5-ml fill volume was 7.14 min. 
The point is highlighted further in a paper which 
looked at how the output of four drugs varied with 
fill volume. The authors state that ‘overall the Side- 
stream offered the best performance for each drug, 
consistently releasing relatively large fractions of the 
initial mass of each of the drugs in aerosol form in 
relatively short times’ (4). Furthermore, in two of the 
four drugs used ‘the percentage of drug released by 
the Sidestream varied by only 15% over the range 2 
to 6 ml .’ (4). 
In conclusion, I would like to quote from a 
research paper produced by Queen’s Medical Centre, 
Nottingham in which the final two sentences state ‘In 
the meantime, the acceptability of this form of treat- 
ment (nebulization) would be improved by attempt- 
ing to shorten rather than extend treatment times (5). 
The most effective way would be to use more concen- 
trated solutions, use smaller fill volumes, and design 
nebulizers with smaller ‘dead volumes’ rather than 
rely on measures such as diluting solution and 
tapping the nebulizer chamber’ (6). 
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